Bristol Myers acquires cell therapy partner 2seventy bio

Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million
(Reuters) -Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares up 76% in premarket trading on Tuesday. Late on Monday, 2seventy said Bristol Myers will acquire all outstanding shares of the company for $5.
Bristol Meyers Squibb to Acquire 2seventy bio
Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.
Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M Deal
Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.
Bristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy Pioneer
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a good deal for BMY or TSVT.
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly all of its market value.
In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma
More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. | More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma,
2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers
Shares of 2seventy bio took flight Tuesday after the biotechnology company agreed to be acquired by partner Bristol Myers Squibb. Bristol Myers is paying $5 a share in cash for 2seventy, a 79% premium to Monday's closing price of $2.80 for the Cambridge, Mass., company.
Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal
Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share agreement between Bristol Myers Squibb and 2seventy bio. Bristol Myers Squibb assumes sole responsibility for Abecma drug product manufacturing and commercialization outside of the U.S.
Business Wire1d
Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders
The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of ...
BioSpace2d
BMS Buys Abecma Partner 2seventy for $286M, Ending Cost Sharing Agreement
Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.
2seventy bio (TSVT) was downgraded to a Hold Rating at Leerink Partners
In a report released today, Daina Graybosch from Leerink Partners downgraded 2seventy bio (TSVT – Research Report) to a Hold, with a price ...
Zacks Investment Research on MSN6h
Biotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY agreed to acquire 2seventy bio, Inc TSVT. Meanwhile, other pipeline and ...